The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | Key findings from CABINET and SEQTOR trials on treatment sequencing for advanced NETs
Nicola Fazio, MD, PhD, Istituto Europeo di Oncologia, Milan, Italy, gives an overview of findings from the CABINET (NCT03375320) and SEQTOR (NCT02246127) trials. CABINET demonstrated significant improvement in progression-free survival (PFS) in patients with advanced neuroendocrine tumors (NET) receiving cabozantinib, with a consistent safety profile. The SEQTOR trial analyzed the sequence of streptozotocin with 5-fluorouracil and everolimus in patients with pancreatic NET (panNET), revealing that streptozotocin with 5-fluorouracil yielded a higher response rate, particularly in grade 2 tumors. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
